Deutivacaftor + Tezacaftor + Vanzacaftor bulk supplier for pharma manufacturers

Deutivacaftor + Tezacaftor + Vanzacaftor Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 10 mg + 50 mg + 125mg

Reference Brands: Alyftrek (USA)

Category: Orphan Drugs

Deutivacaftor + Tezacaftor + Vanzacaftor is available in Tablets and strengths such as 10 mg + 50 mg + 125mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Deutivacaftor + Tezacaftor + Vanzacaftor is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Technical Specifications & Supply Details
Lead Time 7 to 60 days (depending on batch size & schedule)
MOQ As per manufacturer’s batch size
COA Available with every batch
Regulatory Dossier / DMF Available upon request
Export Documentation FSC, COA, Manufacturing License, Product Permission
Standards IP, BP, USP
Certifications WHO-GMP, EU-GMP, USFDA (as applicable)

Deutivacaftor + Tezacaftor + Vanzacaftor can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Product Description:

Alyftrek is a fixed-dose combination oral medication containing vanzacaftor, tezacaftor, and deutivacaftor, developed for the treatment of cystic fibrosis (CF). The drug is specifically indicated for patients aged six years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Vanzacaftor, formulated as vanzacaftor calcium dihydrate, and tezacaftor help improve the processing and trafficking of the defective CFTR protein to the cell surface, while deutivacaftor enhances its function by increasing channel opening probability.

By acting on the underlying genetic defect, Alyftrek improves chloride transport across epithelial cell membranes, helping to hydrate mucus in the lungs and digestive tract. This leads to improved lung function, reduced pulmonary exacerbations, and better overall symptom management in eligible patients. Administered orally once daily, the medication offers a convenient and effective treatment option for cystic fibrosis, supporting long-term disease management and enhancing quality of life. Alyftrek represents a next-generation therapy for CF, providing targeted correction of CFTR protein function in patients with responsive mutations.

Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

 
Alyftrek is used for the treatment of cystic fibrosis in patients aged 6 years and older who have at least one responsive CFTR gene mutation, including the F508del mutation. It helps improve lung function, reduce pulmonary exacerbations, and manage symptoms associated with cystic fibrosis.


Alyftrek contains a combination of three CFTR modulator components: deutivacaftor, tezacaftor, and vanzacaftor. These work together to increase the quantity and function of the CFTR protein at the cell surface.


The trade name of this combination therapy is Alyftrek.


Alyftrek is manufactured and marketed by Vertex Pharmaceuticals Incorporated.


The generic names are deutivacaftor, tezacaftor, and vanzacaftor.


The brand name is Alyftrek.


Alyftrek is manufactured in FDA-, EMA-, and MHRA-approved facilities by Vertex Pharmaceuticals for distribution in the USA, EU, and UK.

Yes, Deutivacaftor + Tezacaftor + Vanzacaftor is available with DMF and other regulatory documents such as COA and MSDS. These can be provided upon request for qualified buyers.

Absolutely. Sample requests are accepted for formulation trials and quality checks. Please submit an enquiry to initiate the process.

Our manufacturing partners are GMP-certified and comply with ISO and WHO standards, ensuring global quality benchmarks.

Lead times vary based on quantity and destination, but most orders are fulfilled within 1–3 weeks. Express shipping options are available.

Yes, Deutivacaftor + Tezacaftor + Vanzacaftor is exported to over 30 countries across Asia, Africa, Europe, and Latin America. We support documentation for customs and regulatory clearance.

Related Products

Arimoclomol

Strength:
47 mg, 62mg, 93mg

Form: Capsules

Reference Brands: MIPLYFFA (USA)

View Details
Doxecitine + Doxribtimine

Strength:
2g+2g

Form: Oral Solution

Reference Brands: Kygevvi (USA)

View Details
Emapalumab-Lzsg

Strength:
10 mg/2 mL, 50 mg/10 mL

Form: Injection

Reference Brands: Gamifant (USA/EU)

View Details
Migalastat Hydrochloride

Strength:
123 mg

Form: Capsules

Reference Brands: Galafold (USA/EU)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.